Printer Friendly

Gene Expression Profiling of the Optic Nerve Head of Patients with Primary Open-Angle Glaucoma.

1. Background

After cataracts, glaucoma is the second-leading cause of blindness worldwide [1], and it has been classified into specific types, including primary glaucoma and its variants [2]. Primary open-angle glaucoma (POAG) is defined as a progressive optic neuropathy with acquired loss of optic nerve fibers [3]. The characteristics of insidious onset and irreversible blindness caused by POAG have made it a major worldwide health concern [4]. As the most common type of glaucoma, POAG accounts for approximately 60-70% cases of glaucoma [5]. Therefore, understanding the mechanisms of POAG and developing novel therapeutic strategies are of great importance.

The altering evacuation of the aqueous humor in POAG always causes an increase in intraocular pressure and causes anatomical damage to the optic nerve. The optic nerve head (ONH) is the site where the optic nerve forms a ganglion with cell axons [6]. It is the likely site of initial damage, including axonal cytoskeleton damage, axonal transport disruption, and putative axonal regeneration, in the glaucomatous eye [7]. Furthermore, the fortified astrocytes of ONH are the targets of elevated intraocular pressure [8]. The pressure-induced axonal injury of the vulnerable ONH has led many researchers to view glaucoma from the perspective of the genetic basis of the ONH. Optic nerve degeneration in glaucoma was observed in individuals harboring common variants of the 9p21 and 8q22 loci [9]. Moreover, interleukin-6type cytokine signaling are associated with gene expression responses in early ONH injury in rat model of glaucoma [10]. Transforming growth factor-[beta]2 is also involved in glaucomatous damage to the ONH [11]. However, genetic studies of POAG from the perspective of ONH are limited.

In this study, differentially expressed genes (DEGs) in normal and POAG ONH samples were identified. Thereafter, enrichment analysis, DEG interaction network construction, transcription factor (TF) prediction, and TF-DEG network analyses were performed successively. These bioinformatics analyses may be useful in identifying ONH marker genes in patients with POAG and provide a basis for developing new therapies for this disease.

2. Materials and Methods

2.1. Microarray Data. Gene expression profiling data of GSE45570 was downloaded from the Gene Expression Omnibus (GEO) database ( geo/) based on the GPL5175 Affymetrix human exon 1.0 ST array. Six normal ONH samples (mean age = 87.67) and 6 ONH samples from patients with POAG (mean age = 88.83) were collected.

2.2. Data Preprocessing and Screening for DEGs. The probes in gene expression matrix were converted into gene names according to the platform annotation information. The expression values of the probes mapped to a given gene were averaged and considered as the final gene expression value for each sample. Thereafter, the missing data were imputed by the K-nearest neighbor (KNN) method using the impute package of R [12], and median normalization was performed using the pre-processCore package of R [13]. Finally, the limma package in R [13] was used to identify significant DEGs in the POAG ONH and normal ONH samples. Pvalue <0.05 and [absolute value of log2 fold change (FC)] > 0.585 were required for each DEGs.

2.3. Pathway and Functional Enrichment Analyses. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation tools for investigators to understand the biological relevance of genes [14]. In this study, DAVID was applied to investigate the main Gene Ontology (GO) functions and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of DEGs involved in POAG. P value < 0.05 was chosen as the cut-off criterion.

2.4. DEG Interaction Network Analysis. ( provides a common interface for a collection of current analytical tools used in genomics, proteomics, and metabolomics studies. In this study, CCancer spider in was applied to implement a global network statistical framework for analyzing mined DEGs and their correlative genes in ONH samples of patients with POAG. The DEG interaction network was obtained with the cut-off criteria of P value <0.01 based on the hypergeometric distribution test.

2.5. TF-DEG Network Construction. The DEGs in the ONH of POAG samples were aligned and annotated with the gene symbols in the TRANSFAC database [15] to screen for potential TFs. DEG-related binding sites for TFs were predicted using the University of California Santa Cruz (UCSC) database. Finally, the TF-DEG network was visualized using Cytoscape [16].

3. Results

3.1. Data Preprocessing and DEG Screening. The normalized microarray data is shown in Figure 1. All boxes representing gene expression values of samples were centered on a straight line after median normalization of microarray data. Thirtyone significant DEGs were identified after screening of DEGs using P value < 0.05 and [absolute value of log2 FC] > 0.585 as the cut-off criteria (Table 1). Among them, there were 11 upregulated DEGs such as the prostaglandin-endoperoxide synthase 2 (PTGS2) gene. Meanwhile, 20 other genes were downregulated, such as the eyes shut homolog (EYS) and interphotoreceptor matrix proteoglycan 2 (IMPG2) genes.

3.2. Functional and Pathway Enrichment Analyses. GO function (Pvalue <0.05) and KEGG pathway (Pvalue <0.05) enrichment analyses were performed to investigate the specific functions associated with DEGs. As shown in Table 2, the upregulated genes were mainly enriched in the terms of nucleosome assembly and chromatin assembly, whereas genes involved in sensory perception and cognition were mainly downregulated. Moreover, signaling by GPCR and olfactory transduction pathways were enriched in the downregulated DEGs. It is noteworthy that the guanine nucleotide-binding protein (G protein) alpha-transducing activity polypeptide 2 (GNAT2) and retinol-binding protein 3 (RBP3) were jointly and significantly enriched in GO terms of sensory perception, cognition, and signaling by GPCR pathway.

3.3. DEG Interaction Network. The associations of DEGs and their related genes were analyzed by CCancer spider at Ten DEGs and 8 other closely related genes were identified and the DEG interaction network was obtained (P value < 0.01) (Figure2). In this network, the downregulated GNAT2 was a disease-related gene, and it was linked with RBP3 by the short-wave-sensitive opsin 1 (OPN1SW).

3.4. TF-DEG Network. TFs of the DEGs were predicted based on TRANSFAC and UCSC. The TF-DEG network was constructed upon integrating DEGs and TFs (Figure 3). The neuronal differentiation 1 (NEUROD1) with the highest node degree of 36 was located in the center of the network.

4. Discussion

Gene expression profiling was systematically analyzed in this study to gain insight into the molecular mechanism of POAG from the perspective of the genetic basis of the ONH. Consequently, 31 DEGs were screened, including 11 upregulated and 20 downregulated genes. Based on pathway and functional enrichment analyses, genes involved in nucleosome assembly, sensory perception, and cognition were enriched by these DEGs. Further, the DEG interaction network and the TF-DEG network analyses indicated that NEUROD1 might be a marker gene in the ONH of patients with POAG.

Certain DEGs, such as EYS, PTGS2, and IMPG2, identified in this study have been demonstrated to be associated with ophthalmic diseases and might participate in the development of POAG. The downregulated EYS was enriched in functional terms of visual perception and sensory perception of light stimulus. EYS is expressed in the photoreceptor layer of the retina, and a mutation in EYS plays a role in autosomal recessive retinitis pigmentosa [17]. Moreover, upregulated PTGS2 found in our study encodes a cyclooxygenase, which acts both as a peroxidase and as a dioxygenase [18]. It was reported that PTGS2, located on chromosome 1q23-q25, might be related to POAG (GLC1A) [19]. Meanwhile, IMPG2, encoding a proteoglycan, contributes to the development of the interphotoreceptor matrix and may play a role in the maintenance and growth of the light-sensitive photoreceptor [20]. Diseases including maculopathy and retinitis pigmentosa type 56 are associated with this gene [21]. All these findings suggest that the DEGs identified in the ONH might be involved in the development of POAG.

The DEG interaction network demonstrated that genes such as GNAT2 and RBP3 which were linked with OPN1SW may be potential markers and may be jointly regulated genes in the ONH of patients with POAG. These genes were jointly enriched in the significant GO functional terms including sensory perception and cognition. Remarkably, GNAT2 is a disease-related gene, as identified in this study. During visual impulses, the coupling of cGMP-phosphodiesterase and rhodopsin transducin is activated by transducin [22]. The alpha subunit of transducin is encoded by GNAT2 [23], and evidence shows that GNAT2 is involved in diseases such as achromatopsia [24] and oligocone trichromacy [25]. Moreover, GNAT2 and OPN1SW are cone-specific markers, and the dysregulation of these genes may be related to retinal disease [26]. Furthermore, RBP3 is a glycoprotein expressed in the interphotoreceptor matrix of the retina [27]; it is also associated with retinitis pigmentosa [28]. Interestingly, the clinical signs of retinopathy in OXYS rats appear by approximately 3 months of age. The phototransduction genes such as GNAT2 and OPN1SW and eye development genes such as GNAT2 and RBP3 are unexpectedly upregulated in OXYS rats at 3 months of age [29]. Hence, the dysregulated GNAT2 and RBP3 associated with OPN1SW might jointly function in the ONH and contribute to the development of POAG.

Notably, the TF-DEG network demonstrated that down-regulated NEUROD1 was significantly linked with 36 TFs, and this gene was identified in the DEG interaction network. Moreover, NEUROD1 promotes the formation of early retinal ganglion cells [30], and retinal ganglion cell counts are associated with early visual field defects of glaucoma [31]. Thus, NEUROD1 might be a key marker gene in the ONH of POAG patients. Early studies on cultured retinal cells have shown that loss of NEUROD1 causes delayed amacrine differentiation, increased bipolar cell population, death of a subset of rod photoreceptors, and increased gliogenesis [32]. Furthermore, knockout of NEUROD1 in mice highlighted a role of this gene in long-term maintenance and survival of photoreceptors and photoreceptor differentiation [33]. More recently, targeted gene deletion studies showed that NEUROD1 is required for the survival of photoreceptors, but not pinealocytes, indicating a specific role for this gene in photoreceptors [34]. Photoreceptors are affected by chronically elevated intraocular pressure and are associated with glaucoma [35]. Optical coherence tomography studies showed that eye damage in glaucoma patients related to structural changes in the photoreceptor layer [36]. This highlighted a crucial role of NEUROD1 in POAG.

In conclusion, we identified 31 significant DEGs between normal ONH and the ONH of patients with POAG based on gene expression profiling. Further, network and TF prediction analyses revealed genes with abnormal expression, including GNAT2, RBP3, and NEUROD1, which might have important implications in POAG. These genes, especially NEUROD1, are involved in different eye diseases. At the genetic level, the presence of abnormally expressed genes further confirmed the hypothesis that the ONH is closely related to the occurrence of POAG. Moreover, our analyses may provide a basis for developing novel therapies for POAG. However, more in-depth experimental studies (such as real-time quantitative polymerase chain reaction) are needed to verify our findings.


Xinrong Wang and Ke Gong are co-first authors. Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Xinrong Wang and Ke Gong participated in the design of this study, and they both performed the statistical analysis. Haiyan Li, Congyi Wang, and Chaoyi Qu performed the study and collected important background information. Hui Li drafted the manuscript. All authors read and approved the final manuscript.


This study was supported by the National Natural Science Foundation of China (Grant no. 81100208).


[1] S. Kingman, "Glaucoma is second leading cause of blindness globally," Bulletin of the World Health Organization, vol. 82, no. 11, pp. 887-888, 2004.

[2] H. A. Quigley, "Glaucoma," Lancet, vol. 377, no. 9774, pp. 1367-1377, 2011.

[3] R. N. Weinreb, C. K. Leung, J. G. Crowston et al., "Primary open-angle glaucoma," Nature Reviews Disease Primers, vol. 2, no. 9422, p. 16067, 2016.

[4] F. M. Wagdy, S. H. Elsayed, H. M. Elsobky, and D. F. Eldegwy, "Early glaucoma surgery in primary open angle glaucoma," Life Science Journal, vol. 11, no. 1, pp. 18-26, 2014.

[5] L. Abdu, "Epidemiological properties of primary open angle glaucoma in Nigeria," Journal of Ophthalmology, vol. 2013, no. 1, p. 402739, 2013.

[6] N. L. Brown, S. Patel, J. Brzezinski, and T. Glaser, "Math5 is required for retinal ganglion cell and optic nerve formation," Development, vol. 128, no. 13, pp. 2497-2508, 2001.

[7] G. Chidlow, A. Ebneter, J. P. Wood, and R. J. Casson, "The optic nerve head is the site of axonal transport disruption, axonal cytoskeleton damage and putative axonal regeneration failure in a rat model of glaucoma," Acta Neuropathologica, vol. 121, no. 6, pp. 737-751, 2011.

[8] C. Dai, P. T. Khaw, Z. Q. Yin, D. Li, G. Raisman, and Y. Li, "Structural basis of glaucoma: the fortified astrocytes of the optic nerve head are the target of raised intraocular pressure," Glia, vol. 60, no. 1, pp. 13-28, 2012.

[9] J. L. Wiggs, B. L. Yaspan, M. A. Hauser et al., "Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma," PLoS Genetics, vol. 8, no. 4 article e1002654, 2012.

[10] E. C. Johnson, T. A. Doser, W. O. Cepurna et al., "Cell proliferation and interleukin-6-type cytokine signaling are implicated by gene expression responses in early optic nerve head injury in rat glaucoma," Investigative Ophthalmology & Visual Science, vol. 52, no. 1,pp. 504-518,2011.

[11] R. Fuchshofer, "The pathogenic role of transforming growth factor- (32 in glaucomatous damage to the optic nerve head," Experimental Eye Research, vol. 93, no. 2, pp. 165-169, 2011.

[12] N. L. Crookston and A. O. Finley, yaImpute: yaImpute: An R Package for k-NN Imputation, 2014.

[13] R. Saito, M. E. Smoot, K. Ono et al., "A travel guide to Cytoscape plugins," Nature Methods, vol. 9,no. 11,pp. 1069-1076,2012.

[14] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44-57, 2008.

[15] B. V. Matys and E. Al, "TRANSFAC: transciptional regulation, from patterns to profiles," Nucleic Acids Research, vol. 31, no. 1, pp. 374-378, 2003.

[16] M. E. Smoot, K. Ono, J. Ruscheinski, P. L. Wang, and T. Ideker, "Cytoscape 2.8: new features for data integration and network visualization," Bioinformatics, vol. 27, no. 3, pp. 431-432, 2011.

[17] M. M. A. El-Aziz, C. A. O'Driscoll, R. S. Kaye et al., "Identification of novel mutations in the ortholog of Drosophila eyes shut gene (EYS) causing autosomal recessive retinitis pigmentosa," Investigative Ophthalmology & Visual Science, vol. 51, no. 8, pp. 4266-4272,2010.

[18] T. Hla and K. Neilson, "Human cyclooxygenase-2 cDNA," Proceedings of the National Academy of Sciences, vol. 89, no. 16, pp. 7384-7388, 1992.

[19] A. Belmouden, M. F. Adam, S. D. de Dinechin et al., "Recombinational and physical mapping of the locus for primary open-angle glaucoma (GLC1A) on chromosome 1q23-q25," Genomics, vol. 39, no. 3, pp. 348-358, 1997.

[20] M. H. Kuehn, E. M. Stone, and G. S. Hageman, "Organization of the human IMPG2 gene and its evaluation as a candidate gene in age-related macular degeneration and other retinal degenerative disorders," Investigative Ophthalmology & Visual Science, vol. 42, no. 13, pp. 3123-3129, 2001.

[21] D. Bandah-Rozenfeld, R. W. Collin, E. Banin et al., "Mutations in IMPG2, encoding interphotoreceptor matrix proteoglycan 2, cause autosomal-recessive retinitis pigmentosa," The American Journal of Human Genetics, vol. 87, no. 2, pp. 199-208, 2010.

[22] M. Abood, J. Hurley, M. Pappone, H. R. Bourne, and L. Stryer, "Functional homology between signal-coupling proteins. Cholera toxin inactivates the GTPase activity of transducin," Journal of Biological Chemistry, vol. 257, no. 18, pp. 10540-10543, 1982.

[23] E. H. Hurowitz, J. M. Melnyk, Y.-J. Chen, H. Kouros-Mehr, M. I. Simon, and H. Shizuya, "Genomic characterization of the human heterotrimeric G protein a, (3, and y subunit genes," DNA Research, vol. 7, no. 2, pp. 111-120, 2000.

[24] T. Rosenberg, B. Baumann, S. Kohl, E. Zrenner, A. L. Jorgensen, and B. Wissinger, "Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations," Investigative Ophthalmology & Visual Science, vol. 45, no. 12, pp. 4256-4262, 2004.

[25] M. Michaelides, G. Holder, K. Bradshaw, D. M. Hunt, J. D. Mollon, and A. T. Moore, "Oligocone trichromacy: a rare and unusual cone dysfunction syndrome," British Journal of Ophthalmology, vol. 88, no. 4, pp. 497-500, 2004.

[26] S. Yoshida, A. J. Mears, J. S. Friedman et al., "Expression profiling of the developing and mature Nrl-/- mouse retina: identification of retinal disease candidates and transcriptional regulatory targets of Nrl," Human Molecular Genetics, vol. 13, no. 14, pp. 1487-1503, 2004.

[27] S.-L. Fong, W.-B. Fong, T. A. Morris, K. M. Kedzie, and C. D. Bridges, "Characterization and comparative structural features of the gene for human interstitial retinol-binding protein," Journal of Biological Chemistry, vol. 265, no. 7, pp. 3648-3653, 1990.

[28] S. Li, Z. Yang, J. Hu et al., "Secretory defect and cytotoxicity: the potential disease mechanisms for the retinitis pigmentosa (RP)-associated interphotoreceptor retinoid-binding protein (IRBP)," Journal of Biological Chemistry, vol. 288, no. 16, pp. 11395-11406, 2013.

[29] O. S. Kozhevnikova, E. E. Korbolina, N. I. Ershov, and N. G. Kolosova, "Rat retinal transcriptome: effects of aging and AMD-like retinopathy," Cell Cycle, vol. 12,no. 11,p. 1745, 2013.

[30] T. Inoue, M. Hojo, Y. Bessho, Y. Tano, J. E. Lee, and R. Kageyama, "Math3 and NeuroD regulate amacrine cell fate specification in the retina," Development, vol. 129, no. 4, pp. 831-842, 2002.

[31] F. A. Medeiros, R. Lisboa, R. N. Weinreb, J. M. Liebmann, C. Girkin, and L. M. Zangwill, "Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma," Ophthalmology, vol. 120, no. 4, pp. 736-744, 2013.

[32] E. M. Morrow, T. Furukawa, J. E. Lee, and C. L. Cepko, "NeuroD regulates multiple functions in the developing neural retina in rodent," Development, vol. 126, no. 1, pp. 23-36, 1999.

[33] M. E. Pennesi, J.-H. Cho, Z. Yanget al., "BETA2/NeuroD1 null mice: a new model for transcription factor-dependent photoreceptor degeneration," The Journal of Neuroscience, vol. 23, no. 2, pp. 453-461, 2003.

[34] M. J. Ochocinska, E. M. Munoz, S. Veleri et al., "NeuroD1 is required for survival of photoreceptors but not pinealocytes: results from targeted gene deletion studies," Journal of Neurochemistry, vol. 123, no. 1, pp. 44-59, 2012.

[35] T. M. Nork, J. N. Ver Hoeve, G. L. Poulsen et al., "Swelling and loss of photoreceptors in chronic human and experimental glaucomas," Archives of Ophthalmology, vol. 118, no. 2, pp. 235-245, 2000.

[36] N. Fan, N. Huang, D. S. C. Lam, and C. K. Leung, "Measurement of photoreceptor layer in glaucoma: a spectral-domain optical coherence tomography study," Journal of Ophthalmology, vol. 2011, p. 264803, 2011.

Xinrong Wang, (1) Ke Gong, (1) Haiyan Li, (1) Congyi Wang, (1) Chaoyi Qu, (1) and Hui Li (2)

(1) Department of Ophthalmology, The Fourth Hospital of Xi'an, Xi'an, Shaanxi 710004, China

(2) Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China

Correspondence should be addressed to Hui Li;

Received 8 November 2016; Revised 1 February 2017; Accepted 14 February 2017; Published 5 April 2017

Academic Editor: Ji-jing Pang

Caption: Figure 1: Microarray chips normalization.

Caption: Figure 2: Differentially expressed genes (DEG) interaction network. Squares represent inputted DEGs; triangles represent intermediate genes recorded in; red nodes represent disease-related genes; blue nodes represent carcinoma-related genes.

Caption: Figure 3: Transcription factor (TF) differentially expressed genes (DEG) network. Red nodes represent upregulated DEGs; green nodes represent downregulated DEGs; yellow triangles represent TFs; arrowed lines represent the regulatory relationship.
Table 1: The 31 significant DEGs between
POAG ONH and normal ONH samples.

Gene         logFC     P value

HIST1H2BE   1.085616   0.018774
ST13P4      0.873623   0.00046
HIST1H2AJ   0.778174   0.025284
AGXT2L1     0.774778   0.028185
PTGS2       0.71795    0.01722
ASPN        0.713362   0.030858
PSME2       0.65883    0.030883
ULBP1       0.648397   0.031441
DPPA3       0.636051   0.009133
FLJ37543    0.594389   0.034072
ITGBL1      0.585321   0.027386
FABP3       -0.60266   0.014561
FSTL5       -0.60642   0.00971
IMPG2       -0.61099   0.027252
DNM1P41     -0.61537   0.005843
RBP3        -0.62018   0.017575
RARRES1     -0.63046   0.02175
OR2M7       -0.65331   0.02169
OR2V2       -0.68567   0.000135
APIP        -0.71479   0.03663
EYS         -0.72694   0.025346
NEUROD1     -0.72925   0.043711
OR13C9      -0.74864   0.006745
GNAT2       -0.74885   0.011052
IMPG1       -0.77855   0.025706
UBQLN4      -0.79455   0.017207
CLUL1       -0.81503   0.037454
SUMO1P3     -0.82912   0.015582
OR4N4       -0.83176   0.013802
GUCA1C      -0.87337   0.035767
OPN1LW      -1.09261   0.009174

DEGs, differentially expressed genes; POAG,
primary open-angle glaucoma;
ONH, optic nerve head; FC, fold change.

Table 2: GO and KEGG pathway enrichment analysis of DEGs.

Category    Ontology/pathway       ID

POAG-UP            BP          GO:0006334
                   BP          GO:0031497
                   BP          GO:0065004
                   BP          GO:0034728
                   CC          GO:0000786

POAG-DOWN          BP          GO:0007600
                   BP          GO:0050890
                   BP          GO:0007601
                   BP          GO:0050953
                   BP          GO:0050877
            REACTOME_PATHWAY   REACT_14797
              KEGG_PATHWAY      hsa04740

Category                    Term                   Gene      P value

POAG-UP             Nucleosome assembly              2     0.030668023
                     Chromatin assembly              2     0.031749223
                Protein-DNA complex assembly         2     0.033189322
                  Nucleosome organization            2     0.033908729
                         Nucleosome                  2     0.038767339

POAG-DOWN            Sensory perception             11      3.23E-09
                         Cognition                  11      9.87E-09
                     Visual perception               7      1.08E-07
            Sensory perception of light stimulus     7      1.08E-07
                Neurological system process         11      1.53E-07
                     Signaling by GPCR               5     0.005027711
                   Olfactory transduction            5      8.87E-04

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs,
differentially expressed genes; BP, biological process; CC, cellular
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Wang, Xinrong; Gong, Ke; Li, Haiyan; Wang, Congyi; Qu, Chaoyi; Li, Hui
Publication:Journal of Ophthalmology
Date:Jan 1, 2017
Previous Article:Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results.
Next Article:A Rabbit Model Study to Determine the Efficacy of a Prototype Corneal Endothelium Protector during Cataract Surgery.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |